Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis

Pirfenidone and nintedanib are oral antifibrotic agents approved for the treatment of idiopathic pulmonary fibrosis (IPF). Real-world data on factors that influence IPF treatment decisions are limited. Physician characteristics associated with antifibrotic therapy initiation following an IPF diagnos...

Descripción completa

Detalles Bibliográficos
Autores principales: LaCamera, Peter P, Limb, Susan L, Haselkorn, Tmirah, Morgenthien, Elizabeth A, Stauffer, John L, Wencel, Mark L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764076/
https://www.ncbi.nlm.nih.gov/pubmed/31558049
http://dx.doi.org/10.1177/1479973119879678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764076/
https://www.ncbi.nlm.nih.gov/pubmed/31558049
http://dx.doi.org/10.1177/1479973119879678

Ejemplares similares